| [1] |
梁金晓, 林仲秋. 《FIGO 2018癌症报告》——子宫肉瘤诊治指南解读[J]. 中国实用妇科与产科杂志, 2018, 34(12): 1366-1371. DOI: 10.19538/j.fk2018120116.
|
| [2] |
Abeler VM, Nenodovic M. Diagnostic immunohistochemistry in uterine sarcomas: a study of 397 cases[J]. Int J Gynecol Pathol, 2011, 30(3): 236-243. DOI: 10.1097/PGP.0b013e318200caff.
pmid: 21464730
|
| [3] |
Park GE, Rha SE, Oh SN, et al. Ultrasonographic findings of low-grade endometrial stromal sarcoma of the uterus with a focus on cystic degeneration[J]. Ultrasonography, 2016, 35(2): 124-130. DOI: 10.14366/usg.15045.
pmid: 26537303
|
| [4] |
杨菁, 刘从容. 子宫内膜间质肿瘤的新认识及研究进展[J]. 中华病理学杂志, 2020, 49(10): 1084-1087. DOI: 10.3760/cma.j.cn112151-20200121-00053.
|
| [5] |
Chiang S, Lee CH, Stewart CJR, et al. BCOR is a robust diagnostic immunohistochemical marker of genetically diverse high-grade endometrial stromal sarcoma, including tumors exhibiting variant morphology[J]. Mod Pathol, 2017, 30(9): 1251-1261. DOI: 10.1038/modpathol.2017.42.
|
| [6] |
Capozzi VA, Monfardini L, Ceni V, et al. Endometrial stromal sarcoma: a review of rare mesenchymal uterine neoplasm[J]. J Obstet Gynaecol Res, 2020, 46(11): 2221-2236. DOI: 10.1111/jog.14436.
|
| [7] |
谢玲玲, 林荣春, 林仲秋. 《2022 NCCN子宫肿瘤临床实践指南(第1版)》解读[J]. 中国实用妇科与产科杂志, 2021, 37(12): 1227-1233. DOI: 10.19538/j.fk2021120113.
|
| [8] |
Li D, Yin N, Du G, et al. A real-world study on diagnosis and treatment of uterine sarcoma in Western China[J]. Int J Biol Sci, 2020, 16(3): 388-395. DOI: 10.7150/ijbs.39773.
pmid: 32015676
|
| [9] |
George S, Feng Y, Manola J, et al. Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors[J]. Cancer, 2014, 120(5): 738-743. DOI: 10.1002/cncr.28476.
pmid: 24222211
|
| [10] |
Pérez-Fidalgo JA, Ortega E, Ponce J, et al. Uterine sarcomas: clinical practice guidelines for diagnosis, treatment, and follow-up, by Spanish group for research on sarcomas (GEIS)[J]. Ther Adv Med Oncol, 2023, 15: 17588359231157645. DOI: 10.1177/17588359231157645.
|
| [11] |
中国医师协会微无创医学专业委员会妇科肿瘤学组, 中国医院协会妇产医院分会妇科肿瘤专业学组. 高级别子宫内膜间质肉瘤诊治中国专家共识(2023年版)[J]. 中国实用妇科与产科杂志, 2023, 39(5): 525-530. DOI: 10.19538/j.fk2023050111.
|
| [12] |
Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase Ⅱ KEYNOTE-158 study[J]. J Clin Oncol, 2020, 38(1): 1-10. DOI: 10.1200/JCO.19.02105.
pmid: 31682550
|
| [13] |
Abouelkhair MB, Shakweer MM, Faisal MM, et al. Diagnostic value of combined BCOR, cyclin D1, and CD10 in differentiating endometrial stromal sarcoma from other uterine spindle cell lesions[J]. Appl Immunohistochem Mol Morphol, 2024, 32(7): 326-335. DOI: 10.1097/PAI.0000000000001213.
pmid: 38961542
|
| [14] |
Akaev I, Yeoh CC, Rahimi S. Update on endometrial stromal tumours of the uterus[J]. Diagnostics (Basel), 2021, 11(3): 429. DOI: 10.3390/diagnostics11030429.
|
| [15] |
Hwang H, Matsuo K, Duncan K, et al. Immunohistochemical panel to differentiate endometrial stromal sarcoma, uterine leiomyosarcoma and leiomyoma: something old and something new[J]. J Clin Pathol, 2015, 68(9): 710-717. DOI: 10.1136/jclinpath-2015-202915.
pmid: 25991737
|
| [16] |
Mohammad N, Stewart CJR, Chiang S, et al. p53 immunohistochemical analysis of fusion-positive uterine sarcomas[J]. Histopathology, 2021, 78(6): 805-813. DOI: 10.1111/his.14292.
pmid: 33118176
|
| [17] |
Zuo X, Jiang W, He YM, et al. High-grade endometrial stromal sarcoma with BCOR rearrangements: clinicopathological analysis of five cases and literature reviews—an extension in understanding of morphological characteristics[J]. Int J Clin Exp Pathol, 2024, 17(8): 245-251. DOI: 10.62347/GDKO4005.
|
| [18] |
Gadducci A, Multinu F, De Vitis LA, et al. Endometrial stromal tumors of the uterus: epidemiology, pathological and biological features, treatment options and clinical outcomes[J]. Gynecol Oncol, 2023, 171: 95-105. DOI: 10.1016/j.ygyno.2023.02.009.
pmid: 36842409
|
)
